-continued

```
Val Arg Gly Asp Ile Asp Val Cys Ala Tyr Phe Thr Pro Ser Asn Ser
        35                  40                  45

Pro Gly Val Ser Glu Ile Arg Phe Ser Trp Asp Arg Lys Thr Ile Gln
    50                  55                  60

Cys Tyr Glu Asn Ile Ile Thr Val Pro Asn Ala Asp Lys Trp Asp Ile
65                  70                  75                  80

Ile Lys Lys Ala Pro Ile Val Asp Asp Phe Ser Lys His Asp Glu Arg
                85                  90                  95

Met Ser Lys Glu Arg Ser Val Asp Asp Ile Ile Val Asp Ala Met Ala
            100                 105                 110

Asp Ala Asp Pro Lys Asp Ala Glu Thr Thr Met Phe Trp Arg Pro Pro
        115                 120                 125

Ile Asp Asp Ser Ser Tyr Val Met Ala Ser Arg Gln Leu Asp Tyr Leu
    130                 135                 140

Ala Lys Asn Val Glu Arg Lys Glu Met Asn Leu Gln Arg Thr Leu Gln
145                 150                 155                 160

Ala Ala Thr Ala Gly Glu Ile Gly Ile Asn Lys Ile Ala Ala Cys Val
                165                 170                 175

Ile Glu Ala Asp Ser Arg Glu Asp Ile Tyr Ile Lys Ser Met
            180                 185                 190
```

What is claimed is:

1. A vector for enhanced expression of at least one first nucleic acid molecule in a cell having a particular phenotype, said vector modified to comprise the first nucleic acid molecule and at least one second nucleic acid molecule encoding a transcription factor and a translation factor, wherein there is substantially co-temporal expression of the first and second nucleic acid molecules with respect to the phenotype of the cell, whereby expression of the second nucleic acid molecule enhances expression of the first nucleic acid molecule by enhancing transcription or transcription and translation.

2. The vector of claim **1** wherein the first nucleic acid molecule is operably linked to a first promoter and the second nucleic acid molecule is operably linked to a second promoter, and the first and second promoters function substantially co-temporally.

3. The vector of claim **2** wherein the first and second nucleic acid molecules are at different loci within the vector.

4. The vector of claim **2** wherein the first and second nucleic acid molecules are at the same locus within the vector.

5. The vector of claim **1** wherein the first nucleic acid molecule and the second nucleic acid molecule are operably linked to the same promoter.

6. The vector of claim **1** wherein transcription factor is of poxvirus origin.

7. The vector of claim **6** wherein the transcription factor is from a vaccinia virus.

8. The vector of claim **7** wherein the transcription factor is from an open reading frame selected from the group consisting of H4L, D6, A7, G8R, A1L, A2L, H5R, and combinations thereof.

9. The vector of claim **1** wherein the vector has a particular phenotype and the time of expression is matched with the phenotype of the vector.

10. The vector of claim **1** wherein the translation factor effects inhibition of eIF-2α phosphorylation or inhibition of PKR phosphorylation or otherwise sequesters dsRNA, decreasing the cellular dsRNA content which increases the effective concentration of dsRNA.

11. The vector of claim **10** wherein said at least one second molecule is selected from the group consisting of: a K3L open reading frame, an E3L open reading frame, a VAI RNA open reading frame, an EBER RNA open reading frame, a sigma 3 open reading frame, a TRBP open reading frame, and combinations thereof.

12. The vector of claim **1** wherein said first nucleic acid molecule encodes a molecule selected from the group consisting of an epitope of interest, a biological response modulator, a growth factor, a recognition sequence, and a fusion protein.

13. The vector of claim **1** which is a recombinant virus.

14. The vector of claim **13** which is a recombinant poxvirus.

15. The vector of claim **1** wherein the transcription factor is a viral transcription factor.

16. The vector of claim **1** wherein the translation factor is a viral translation factor.

17. The vector of claim **16** wherein the transcription factor is a viral transcription factor.

18. A vector which is vCP1452 or vCP1433.

19. A method for preparing a vector as claimed in claim **1** comprising modifying the vector to comprise the at least one second nucleic acid molecule, and optionally also modifying the vector to comprise the first nucleic acid molecule, so that there is substantially co-temporal expression of the first and second nucleic acid molecules with respect to the phenotype of the cell.

20. The method for claim **19** comprising operably linking the first nucleic acid molecule to a first promoter and the second nucleic acid molecule to a second promoter, wherein the first and second promoters are functional substantially co-temporally.

21. The method for claim **19** comprising operably linking the first and second nucleic acid molecules to a promoter.

22. An immunological, immunogenic or vaccine composition comprising the vector of claim **1** and a pharmaceutically acceptable carrier or diluent.

23. A method for generating an immunological or immunogenic response in a host comprising administering to the host the composition of claim **22**.